Viking Therapeutics, Inc.VKTXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +11.08% | +11.22% | +8.32% | +1.58% | +1.27% |
| Weighted Average Shares Diluted Growth | +11.08% | +11.22% | +8.32% | +1.58% | +1.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +145.10% | +146.50% | -10.39% | -12.57% | -21.16% |
| Book Value per Share Growth | +122.82% | +127.17% | -16.28% | -14.97% | -22.75% |
| Debt Growth | -7.63% | -11.19% | -15.33% | -20.18% | -38.87% |
| R&D Expense Growth | +23.97% | +51.14% | +71.73% | +153.07% | +294.79% |
| SG&A Expenses Growth | +54.97% | +73.64% | +41.20% | +40.21% | -37.49% |